featured
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
N. Engl. J. Med 2021 Dec 11;[EPub Ahead of Print], FL Locke, DB Miklos, CA Jacobson, MA Perales, MJ Kersten, OO Oluwole, A Ghobadi, AP Rapoport, J McGuirk, JM Pagel, J Muñoz, U Farooq, T van Meerten, PM Reagan, A Sureda, IW Flinn, P Vandenberghe, KW Song, M Dickinson, MC Minnema, PA Riedell, LA Leslie, S Chaganti, Y Yang, S Filosto, J Shah, M Schupp, C To, P Cheng, LI Gordon, JR Westin,From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.